Aligos Q3 net loss $18.0M ($0.41/shr); raises $92M in October PIPE

Aligos Therapeutics, Inc.

2023-Q3 EPS reported -$1.38 revenue$5,519,000

Net loss $18.0M ($0.41 per share) vs $18.6M ($0.44) in Q3 2022.
Cash, equivalents & investments $70.4M at Sep 30, down from $125.8M at Dec 31, 2022.
Closed $92M private placement in October 2023; projects cash runway through end of 2025.
FDA cleared IND for NASH THR-β agonist ALG-055009; Phase 2a startup underway.
Awarded $8.5M NIAID contract to advance coronavirus protease inhibitor ALG-097558.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aligos Therapeutics, Inc. reported the third quarter 2023 results: net income $18.0 million, EPS $(0.41).

Period: the third quarter 2023
Net income: $18.0 million
EPS: $(0.41)
Result: reported results

Exact text from the filing

Net losses for the three months ended September 30, 2023 were $18.0 million or basic and diluted net loss per common share of $(0.41)

View on SEC.gov

Browse all earnings releases →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-006671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.